Revolution Medicines (RVMD) Return on Sales (2019 - 2024)

Revolution Medicines' Return on Sales history runs 6 years deep, the most recent figure standing at 7.69% for Q3 2024.

• On a quarterly basis, Return on Sales fell 757.0% year-over-year to 7.69% in Q3 2024; TTM through Sep 2024 was 7.69%, a 757.0% decrease from a year earlier, with the FY2023 full-year figure at 0.38%, down 31.0% from the prior year.
• Return on Sales declined to 7.69% in Q3 2024 per RVMD's latest filing, from 7.05% in the prior quarter.
• Across five years, Return on Sales topped out at 0.02% in Q1 2020 and bottomed at 7.69% in Q3 2024.
• The 5-year median for Return on Sales is 0.08% (2022), against an average of 1.03%.
• Across the five-year window, Return on Sales advanced 26 bps in 2022 and tumbled 757 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.04% in 2020, then plunged by 42 bps to 0.06% in 2021, then surged by 34 bps to 0.04% in 2022, then slumped by 5945 bps to 2.23% in 2023, then plunged by 245 bps to 7.69% in 2024.
• Per Business Quant, the three latest RVMD Return on Sales figures stand at 7.69% (Q3 2024), 7.05% (Q2 2024), and 1.07% (Q1 2024).